CoChat

Clinical and metabolic effects associated with weight changes and obeticholic acid in non‐alcoholic steatohepatitis

Open access
Hameed, B., Terrault, N. A., Gill, R. M., Loomba, R., Chalasani, N., Hoofnagle, J. H., Van Natta, M. L., for the NASH CRN · 2018 · Alimentary Pharmacology & Therapeutics
Cited by 73

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: Background: In a 72‐week, randomised controlled trial of obeticholic acid (OCA) in non‐alcoholic steatohepatitis (NASH), OCA was superior to placebo in improving serum ALT levels and liver histology. OCA therapy also reduced weight. Aims: Because weight loss by itself can improve histology, to perform a post hoc analysis of the effects of weight loss and OCA treatment in improving clinical and metabolic features of NASH. Methods: The analysis was limited to the 200 patients with baseline and end‐of‐treatment liver biopsies. Weight loss was defined as a relative decline from baseline of 2% or more at treatment end. Results: Weight loss occurred in 44% (45/102) of OCA and 32% (31/98) of placebo‐treated patients (P = 0.08). The NAFLD Activity score (NAS) improved more in those with than without weight loss in both the OCA‐ (−2.4 vs −1.2, P<0.001) and placebo‐treated patients (−1.2 vs −0.5, P = 0.03). ALT levels also improved in those with vs without weight loss in OCA‐ (−43 vs −34 U/L, P = 0.12) and placebo‐treated patients (−29 vs −10 U/L, P = 0.02). However, among those who lost weight, OCA was associated with opposite effects from placebo on changes in alkaline phosphatase (+21 vs −12 U/L, P<0.001), total (+13 vs −14 mg/dL, P = 0.02) and LDL cholesterol (+18 vs −12 mg/dL, P = 0.01), and HbA1c (+0.1 vs −0.4%, P = 0.01). Conclusions: OCA leads to weight loss in up to 44% of patients with NASH, and OCA therapy and weight loss have additive benefits on serum aminotransferases and histology. However, favourable effects of weight loss on alkaline phosphatase, lipids and blood glucose seen in placebo‐treated patients were absent or reversed on OCA treatment. These findings stress the importance of assessing concomitant metabolic effects of new therapies of NASH. Clinical trial number: NCT 01265498.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.14492

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 15

  1. 10.1002/hep.28431 · DOI · Paper page
  2. 10.1016/j.jpeds.2012.08.043 · DOI · Paper page
  3. 10.1053/j.gastro.2014.11.039 · DOI · Paper page
  4. 10.1002/hep.27678 · DOI · Paper page
  5. 10.2337/db13-0299 · DOI
  6. 10.1074/jbc.M510258200 · DOI · Paper page
  7. 10.1021/jm049904b · DOI · Paper page
  8. 10.1194/jlr.M001602 · DOI · Paper page
  9. 10.1111/apt.12352 · DOI · Paper page
  10. 10.1002/hep.20701 · DOI · Paper page
  11. 10.1007/BF03085956 · DOI
  12. 10.1016/S0895-4356(00)00314-0 · DOI · Paper page
  13. 10.1194/jlr.R024794 · DOI · Paper page
  14. 10.1161/ATVBAHA.109.197897 · DOI · Paper page
  15. 10.1111/j.1365-2036.2008.03752.x · DOI

Cited by

See all 73

Metadata

Authors
Hameed, B., Terrault, N. A., Gill, R. M., Loomba, R., Chalasani, N., Hoofnagle, J. H., Van Natta, M. L., & CRN, F. T. N.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2018-01-14
Volume
47
Issue
5
Pages
645-656
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2782978792
Cited by
73
References
7
FWCI
7.33
Type
journal article
Language
en
Open access
bronze
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713)
  • National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR000058)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and metabolic effects associated with weight changes and obeticholic acid in non‐alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1111/apt.14492
The paper
Hameed, B., Terrault, N. A., Gill, R. M., Loomba, R., Chalasani, N., Hoofnagle, J. H., Van Natta, M. L., & CRN, F. T. N. (2018). Clinical and metabolic effects associated with weight changes and obeticholic acid in non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14492

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.